Interference of cationic polymeric nanoparticles with clinical chemistry tests—Clinical relevance

• Published in: International journal of pharmaceutics Vol. 473; no. 1-2; pp. 599 - 606
• Main Authors: Shcharbin, Dzmitry, Shcharbina, Natallia, Milowska, Katarzyna, de la Mata, Francisco Javier, Muñoz-Fernandez, Maria Angeles, Mignani, Serge, Gomez-Ramirez, Rafael, Majoral, Jean-Pierre, Bryszewska, Maria
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01-10-2014; Elsevier
• Subjects: Chemical Sciences; Clinical chemistry test; Clinical Chemistry Tests; Coordination chemistry; Dendrimer; Dendrimers - chemistry; Enzyme; Nanoparticle; Nanoparticles - chemistry; Phosphorus - chemistry; Protein; Serum - chemistry; Silanes - chemistry; Clinical chemistry test; Dendrimer; Nanoparticle; Enzyme; Protein
• ISSN: 0378-5173; 1873-3476
• DOI: 10.1016/j.ijpharm.2014.07.054

[Display omitted]
The development of medical nanosystems requires knowledge of their behavior in vivo. Clinical chemistry tests are widely used to estimate the systemic toxicity of nanoparticles. In this paper we have explored the impact of small positively charged nanoparticles–poly(amidoamine), phosphorous and carbosilane dendrimers – on biochemical parameters of standardized serum in vitro. All the dendrimers could shift the main biochemical parameters. Thus, in the case of patients having the normal, but ‘boundary’, values of biochemical parameters, nanoparticle-induced changes can be wrongly interpreted as evidence of some dysfunctions (hepatic, renal, etc.). Moreover, the effects of nanoparticles of metals, carbon nanotubes, quantum dots, fullerenes, dendrimers having been sized up to 4000nm and the hundreds of reactive groups, can be significantly higher. Thus, preliminary evaluation of any nanomaterial in vitro is required in clinical chemistry tests before its application in vivo to draw the correct conclusions and benefit animals.